CPC’s GMP Manufacturing Facility Passes German Inspection
Chinese Peptide Company, a public Hangzhou-based CDMO (Stock Symbol: 002390) is pleased to announce that our GMP manufacturing facility has successfully passed its inspection by the competent authority of Germany as an“active substance manufacturer that has been inspected in accordance with Art. 111 (1) Directive 2001/83/EC transposed in the following national legislation: Sect 64 para 1 Arzneimittelgesetz (German Drug Law).
The GMP inspection was carried out in order to clear CPC to develop and manufacture a specific NCE for an undisclosed European biopharmaceutical partner.
Comment from Shawn Lee, CEO and Founder of Chinese Peptide Company.
“We are very pleased with the positive EMA inspection results as this marks an important milestone for CPC groups and its quality program. In addition to the inspection by the European Medicines Agency and German authority, CPC has also been inspected by the United States (FDA), Korea (MFDS) and China (NMPA). This inspection also establishes CPC as a central player in the European peptide API markets – for new chemical entities (NCEs) and generic peptide APIs and emerging markets across the globe.”
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance